CinRx Pharma Announces First Study Participant Dosed in CinFina’s Phase I Multiple Ascending Dose (MAD) Study of CIN-109 for the Treatment of Obesity

CinRx Pharma, a mosaic of biotechnology companies accelerating transformational new medicines to patients, announced today the first study participant has been dosed in CinFina’s Phase 1 multiple ascending dose (MAD) study of CIN-109.

CinFina Pharma In-Licenses Obesity Portfolio

CinFina Pharma, LLC. announced today that it has signed an agreement with Janssen Sciences Ireland Unlimited Company (“Janssen”), one of the Janssen Pharmaceutical Companies of J&J.

INVESTOR INQUIRIES

CAREER INQUIRIES

GENERAL INQUIRIES